Biden finds 'following the science' isn't so easy
Sometimes, following the science isn't so easy — especially when "the science" is in flux.
That's certainly the case with the Biden administration's plan to roll out COVID-19 booster shots to already-vaccinated individuals. The White House pledged in August to start rolling out the new jabs on a widespread basis starting Sept. 20, but it's increasingly clear that the whole process is more than a bit messy — two FDA vaccine officials resigned last month, reportedly over their opposition to the administration's booster plan, then on Monday joined a larger group of 18 scientists who say there isn't enough data to support a widespread booster campaign.
The implication? President Biden got ahead of the science.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
"Although the idea of further reducing the number of COVID-19 cases by enhancing immunity in vaccinated people is appealing, any decision to do so should be evidence-based and consider the benefits and risks for individuals and society," the group wrote in The Lancet medical journal.
As New York magazine reports today, there are a number of moving parts in the debate. On the one hand, there are concerns about waning immunity among vaccinated people; on the other hand, those folks still seem to have pretty good protection against severe illness and death. Israel is already giving boosters, and early data suggests that — for older people at least — the extra shots do improve immunity. Then again, the Lancet authors warn that the side effects from boosters given too soon or too frequently could exacerbate the widespread vaccine hesitancy that has helped the pandemic persist in the United States. Complicating all of this: The World Health Organization has warned against a widespread booster campaign while much of the planet is still waiting for its first shot.
What's a president — especially one who has vowed repeatedly to "follow the science" — to do?
When Donald Trump was in charge, it was easy for Democrats to pledge to follow the science on COVID because Trump so plainly didn't, preferring to focus on his own political well-being. But in an ongoing emergency, when scientists themselves can't agree on a course of action — and when there are ethical questions that don't lend themselves to clear "right or wrong" answers — the slogan's insufficiency reveals itself. Even with the best of intentions, politics will still be a factor: Biden's poll ratings are still slipping, and he needs to be seen doing something.
"Follow the science" sounds easy and simple. In the real world, though, the buck doesn't stop in a laboratory, but in the Oval Office.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Joel Mathis is a writer with 30 years of newspaper and online journalism experience. His work also regularly appears in National Geographic and The Kansas City Star. His awards include best online commentary at the Online News Association and (twice) at the City and Regional Magazine Association.
-
Today's political cartoons - November 16, 2024
Cartoons Saturday's cartoons - tears of the trade, monkeyshines, and more
By The Week US Published
-
5 wild card cartoons about Trump's cabinet picks
Cartoons Artists take on square pegs, very fine people, and more
By The Week US Published
-
How will Elon Musk's alliance with Donald Trump pan out?
The Explainer The billionaire's alliance with Donald Trump is causing concern across liberal America
By The Week UK Published
-
Biden arrives in Peru for final summits
Speed Read President Joe Biden will meet Chinese President Xi Jinping, visit the Amazon rainforest and attend two major international summits
By Peter Weber, The Week US Published
-
'The burden of the tariff would be regressive'
Instant Opinion Opinion, comment and editorials of the day
By Justin Klawans, The Week US Published
-
Should Sonia Sotomayor retire from the Supreme Court?
Talking Points Democrats worry about repeating the history of Ruth Bader Ginsburg
By Joel Mathis, The Week US Published
-
'The problem with deliverism is that it presumes voters will notice'
Instant Opinion Opinion, comment and editorials of the day
By Justin Klawans, The Week US Published
-
US election: who the billionaires are backing
The Explainer More have endorsed Kamala Harris than Donald Trump, but among the 'ultra-rich' the split is more even
By Harriet Marsden, The Week UK Published
-
US election: where things stand with one week to go
The Explainer Harris' lead in the polls has been narrowing in Trump's favour, but her campaign remains 'cautiously optimistic'
By Harriet Marsden, The Week UK Published
-
Donald Trump and the fascism debate
Talking Points Democrats sound the alarm, but Republicans say 'it's always the F-word'
By Joel Mathis, The Week US Published
-
Harris keeps her crime policies close to the vest
The Explainer How a post-pandemic crime wave changed the Democratic nominee's priorities
By David Faris Published